<DOC>
	<DOCNO>NCT01512667</DOCNO>
	<brief_summary>This study investigate compare pharmacokinetics single 50 mg dose odanacatib administer participant impaired renal/kidney function healthy match control group .</brief_summary>
	<brief_title>Pharmacokinetic Assessment Single-Dose Odanacatib ( MK-0822 ) Subjects With Severe Renal Insufficiency ( MK-0822-067 )</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Not currently pregnant , nurse planning pregnant throughout course study ; individual agrees use specify contraception per protocol requirement duration study . Note : All female must serum pregnancy test ensure document negative test result prior inclusion study . Body Mass Index ( BMI ) 39.49kg/m^2 Assessed good health , include clinically significant cardiac abnormality base result electrocardiogram ( ECG , perform prescreening and/or prior administration study drug . Meets requirement study regard current medication profile include : prescribed medication , caffeine , alcohol , overthecounter drug , herbal nutritional product ; expect nonuse recreational ( illicit ) drug associate misuse , abuse and/or addiction . Agrees adhere smoke dietary restriction associate study . Possess ability understand study , grant voluntary inform consent , willingly comply study requirement . Inclusion Criterion Specific Participants Renal/Kidney Insufficiency : Creatinine clearance &lt; 30 mL/min Inclusion Criterion Specific Healthy Volunteers : Creatine clearance â‰¥ 90 mL/min ( healthy volunteer ) Does meet age requirement , mentally legally incapacitate , expect significant emotional problem , and/or history clinically significant psychiatric disorder . Diagnosed disease medical condition may pose risk participant may confound study result . Has demonstrate suspect stenosis ( narrow ) renal artery , and/or renal transplant and/or kidney removal . Has current , unstable , significant organ system disease ( ) and/or cancer ( ) . Has surgical procedure , donate 1 unit blood receive another investigational study medication within 4 week prior study 's first dose investigational product . Unable refrain anticipates use new medication , include prescription nonprescription drug and/or herbal remedy . Exceptions may include medication prescribed prevention disease preservation healthy life . Uses medication agent potential significantly alter renal/kidney function . Unable avoid take diuretic ( within 4 hour prior dose investigational product ) phosphate binder contain aluminum , calcium lanthanum salt ; iron supplement metal cation ; antacid ; multivitamin contain iron zinc ( within 8 hour prior dose 4 hour dose investigational product ) . Note : individual prescribe diuretic must stable dose least 4 week prior study 's start date order participate . History multiple and/or severe allergy , lifethreatening reaction drug agent , and/or inability tolerate prescription nonprescription drug and/or food .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>